AUA 2017: The Effective Period of First Androgen-Deprivation Therapy Becomes a Prognostic Factor in Docetaxel Chemotherapy for Castration-Resistant Prostate Cancer Patients

Boston, MA (UroToday.com) Dr. Shigeta presented their retrospective, single center, review to determine the duration of 1st ADT and duration from onset of castration resistance to first docetaxel course. Additionally, this group sought to determine if this was associated with survival outcomes.
201 patients were included in their cohort analysis with a median cancer specific survival of 21.5 months and a progression free survival of 13.5 months. 60.2% of patients achieved PSA nadir <0.2ng/ml. Multivariate analysis demonstrated that presence of visceral metastasis (HR 1.92, p=0.002), duration of ADT <16 months (HR 2.70, p<0.001), and time to start docetaxel >12 months (HR 1.64, p=0.004) were associated with worse progression free survival. Multivariate analysis also indicated that first ADT response <16 months, pretreatment PSA level ≥20 ng/ml, visceral metastasis, and ALP ≥284 were independent prognostic factors for CSS (HR=2.28, HR=1.69, HR=2.65, and HR=1.98, respectively).

This data indeed demonstrates that duration of 1st ADT is useful in predicting treatment response for castrate resistant prostate cancer patients treated with first line docetaxel therapy. Future studies are needed to corroborate this data.

Presented by: Keisuke Shigeta, MD

Authors: Keisuke Shigeta, Takeo Kosaka, Ryuichi MIzuno, Toshiaki Shinojima, Eiji KIkuchi, Akira MIyajima, Tokyo, Japan, Hitoshi Tanoguchi, Kanagawa, Japan, Shintaro Hasegawa, Utsunomiya, Japan, and Mototsugu Oya

Institution: Keio University School of Medicine, Tokyo, Japan

Written By: David B. Cahn, DO, MBS, Fox Chase Cancer Center, Philadelphia, PA
Twitter: @dbcahn

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe